Questions?arveonix@protonmail.com•Telegram @arveonix

Last updated:

ARVEONIX CJC-1295 (without DAC) 10mg + Ipamorelin 10mg research product box and vial
Peptide blends · SKU CP20

CJC-1295 (without DAC) 10mg + Ipamorelin 10mg

$120.00 AUD
In stock
Free shipping Australia-wideOrders over $150

A higher-strength research blend combining CJC-1295 without DAC and Ipamorelin for complementary GHRH and ghrelin-receptor signalling studies.

ProductCJC-1295 (without DAC) 10mg + Ipamorelin 10mg
SKUCP20
CategoryPeptide blends
Listed price$120.00 AUD
AvailabilityIn stock
Confirm current availability when making an enquiry.

What is CJC-1295 (without DAC) + Ipamorelin?

This ARVEONIX blend combines CJC-1295 without DAC 10mg with Ipamorelin 10mg. The formulation brings together a GHRH-pathway analogue and a ghrelin-receptor agonist within one research product.

The scientific rationale for studying these compounds together is pathway complementarity rather than molecular identity. Each component engages a different upstream receptor system involved in pituitary endocrine signalling.

Research category

Peptide blends

ARVEONIX format

CJC-1295 (without DAC) 10mg + Ipamorelin 10mg · SKU CP20

Primary research context

Dual-pathway endocrine signalling

Catalogue status

In stock · $120.00 AUD

Dual-pathway endocrine signalling.

CJC-1295 without DAC is researched through GHRH receptor signalling, while Ipamorelin is primarily associated with GHS-R1a. Both can influence pituitary signalling through distinct upstream mechanisms.

Studies of a combined formulation need to account for relative concentration, temporal dynamics and potential interaction effects rather than assuming the effects of each component are simply additive.

Common research themes.

CJC-1295 without DAC

Shorter-acting GHRH-pathway analogue used in endocrine research.

Ipamorelin

Selective ghrelin-receptor agonist studied in secretagogue signalling.

Pituitary signalling

Research into converging regulation of growth-hormone release.

Blend pharmacology

Investigation of interaction, timing and formulation effects.

Research considerations.

Research findings should always be interpreted within the experimental system in which they were produced. Cell, receptor, tissue, animal and human studies can answer different questions, and results from one model should not automatically be treated as established outcomes in another.

ARVEONIX product pages therefore focus on molecule identity, pathway biology and published research themes rather than presenting experimental observations as guaranteed effects. The information here is not a dosing, treatment or individual-use recommendation.

CJC-1295 FAQs.

What is in the CP20 blend?

CJC-1295 without DAC 10mg plus Ipamorelin 10mg.

Does CJC-1295 without DAC target GHS-R1a?

No. It is associated with the GHRH receptor pathway.

What receptor does Ipamorelin target?

Ipamorelin is primarily associated with GHS-R1a.

Why combine two pathways in research?

It allows investigation of complementary upstream signalling that converges on pituitary endocrine regulation.

How does CP20 differ from CP10?

The listed components are the same, but CP20 contains the higher stated strengths.

What is the SKU?

This product is listed under SKU CP20.

Does the page recommend a dose?

No.